Yangsen Cao

Naval Medical University

H指数:11

被引数:454

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Stage III Lymph Node-Positive Non-Small-Cell Lung Cancer Patients With or Without Lymph Node Irradiation by Stereotactic Body Radiation Therapy: Propensity Score-Matched Analysis

III期淋巴结阳性非小细胞肺癌患者采用立体定向体部放射治疗进行或不进行淋巴结照射：倾向性评分匹配分析

Clinical Respiratory Journal

IF2.3

2026-05-080

OAAI

Stereotactic body radiation therapy plus adoptive vNKT cell therapy for pancreatic cancer: protocol of a phase II trial

立体定向体部放射治疗联合适应vNKT细胞疗法治疗胰腺癌：一项II期试验方案

immunotherapy

IF2.3

2025-07-160

ADJUPANC protocol: a phase III study of adjuvant chemotherapy versus chemoradiotherapy for pancreatic cancer

ADJUPANC协议：一项关于胰腺癌辅助化疗与化学放疗比较的III期研究

Future Oncology

IF2.6

2025-06-290

PRE

Central-boost Ablative Radiation Therapy for Solid Tumors: Study Protocol of a Single-arm, Phase II Trial (CBART)

中央提升式烧蚀放射疗法治疗实体瘤：一项单臂、II期试验（CBART）的研究方案

Technology in Cancer Research & Treatment

IF2.8

2025-06-120

Stereotactic body radiation therapy for the primary tumor and oligometastases versus the primary tumor alone in patients with metastatic pancreatic cancer

转移性胰腺癌患者的原发性肿瘤和寡转移的立体定向放射治疗与单独的原发性肿瘤治疗

RADIATION ONCOLOGY

IF3.2

2024-08-192

OAAI

Immune profiling of pancreatic cancer for radiotherapy with immunotherapy and targeted therapy: Biomarker analysis of a randomized phase 2 trial

RADIOTHERAPY AND ONCOLOGY

IF5.3

2024-01-011

PRE

Efficacy and toxicity of stereotactic body radiotherapy for un-resectable stage III non-small cell lung cancer patients unfit for concurrent chemoradiation therapy: a retrospective study (vol 18, 140, 2023)

RADIATION ONCOLOGY

IF3.2

2023-10-110

OAAI

Efficacy and toxicity of stereotactic body radiotherapy for un-resectable stage III non-small cell lung cancer patients unfit for concurrent chemoradiation therapy: a retrospective study

RADIATION ONCOLOGY

IF3.2

2023-08-243

OAAI

Dose evaluations of organs at risk and predictions of gastrointestinal toxicity after re-irradiation with stereotactic body radiation therapy for pancreatic cancer by deformable image registration

FRONTIERS IN ONCOLOGY

IF3.3

2023-01-301

OAAI

Effect of stereotactic body radiotherapy dose escalation plus pembrolizumab and trametinib versus stereotactic body radiotherapy dose escalation plus gemcitabine for locally recurrent pancreatic cancer after surgical resection on survival outcomes: A secondary analysis of an open-label, randomised, controlled, phase 2 trial

ECLINICALMEDICINE

IF10

2023-01-017

OAAI

Protocol of the integrated boost to the dominant intraprostatic nodule in stereotactic body radiation therapy for localized prostate cancer

FUTURE ONCOLOGY

IF2.6

2022-12-121

PRE

Re-Irradiation With Stereotactic Body Radiotherapy for In-Field Recurrence of Pancreatic Cancer After Prior Stereotactic Body Radiotherapy: Analysis of 24 Consecutive Cases

FRONTIERS IN ONCOLOGY

IF3.3

2021-11-023

OAAI

Stereotactic body radiation therapy with sequential S-1 for patients with locally advanced pancreatic cancer and poor performance status: An open-label, single-arm, phase 2 trial

RADIOTHERAPY AND ONCOLOGY

IF5.3

2021-09-017

PRE

Development and Validation of Multicenter Predictive Nomograms for Locally Advanced Pancreatic Cancer After Chemoradiotherapy

FRONTIERS IN ONCOLOGY

IF3.3

2021-06-084

OAAI

Failure patterns and outcomes of dose escalation of stereotactic body radiotherapy for locally advanced pancreatic cancer: a multicenter cohort study

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY

IF4.2

2020-12-1416

OAAI

Validation of the eighth edition of the AJCC staging system for patients with pancreatic adenocarcinoma initially receiving chemoradiotherapy and proposal of modifications

CANCER BIOLOGY & MEDICINE

IF8.4

2020-01-011

OAAI

Stereotactic Radiation Therapy (SRT) for Brain Metastases of Multiple Primary Tumors: A Single Institution Retrospective Analysis

FRONTIERS IN ONCOLOGY

IF3.3

2019-12-108

OAAI

Patterns of Local Failure After Stereotactic Body Radiation Therapy and Sequential Chemotherapy as Initial Treatment for Pancreatic Cancer: Implications of Target Volume Design

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

IF6.5

2019-05-0162

PREAI

Re-irradiation with SBRT for pancreatic cancer: dose summation and toxicity

RADIOTHERAPY AND ONCOLOGY

IF5.3

2019-04-010

OAAI

Patterns of local failure after SBRT for pancreatic cancer: implications of target volume design

RADIOTHERAPY AND ONCOLOGY

IF5.3

2019-04-010

OAAI

Yangsen Cao

个人简介

教育背景

工作经历

荣誉奖项

研究方向